Abstracts tagged "Myositis"

Abstract Number: 2066 • ACR Convergence 2025
Psychosocial Factors Strongly Influence Subjective Well-being in Patients with Idiopathic Inflammatory Myopathies
Meera Shah¹, Emilia Naseva², Tsvetelina Velikova³, Tamar Rubinstein⁴, Manali Sarkar⁵, Lavanya Mangla⁶, Oliver Distler⁷, Ingrid de Groot⁸, Lisa Christ⁹, Carlo Vinicio Caballero Uribe¹⁰, Ai Lyn Tan¹¹, Abraham Edgar Gracia Ramos¹², Vincenzo Venerito¹³, Vikas Agarwal¹⁴ and Latika Gupta¹⁵, ¹Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, ²Faculty of Public Health, Medical University of Sofia, ¹⁵ Acad. Ivan Evstratiev Geshov, ¹⁶⁰⁶ Sofia; Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ³Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ⁴Albert Einstein College of Medicine, White Plains, NY, ⁵Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁶Maulana Azad Medical College, ²-Bahadurshah Zafar Marg, New Delhi, New Delhi, India, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁸The Myositis Association, Rotterdam, Netherlands, ⁹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Bern, Switzerland, ¹⁰Department of Medicine, Hospital Universidad del Norte, Barranquilla, Atlantico, Colombi, Barranquilla, Colombia, ¹¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ¹²Department of Internal Medicine, General Hospital, National Medical Center “La Raza”, Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. ⁰²⁹⁹⁰ Mexico City, Mexico., Mexico City, Mexico, ¹³Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁵School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Traditional clinical measures are well established in idiopathic inflammatory myopathies (IIM), yet exploration of subjective well-being (SWB) remains limited. SWB assessment facilitates holistic patient…
Abstract Number: 1219 • ACR Convergence 2025
Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy
Vasiliki Syrmou¹, Ioannis Alexiou², Christos Liaskos³, Eleni Patrikiou³, THEODORA SIMOPOULOU⁴, Christina Katsiari⁵ and Dimitrios Bogdanos⁶, ¹University General Hospital of Larisa, University of Thessaly, Faculty of Medicine, Larisa, Greece, ²University General Hospital of Larisa, Larissa, Greece, ³University of Thessaly, Faculty of Medicine, Larisa, Greece, ⁴University Hospital of Larissa, Greece, Larissa, Greece, ⁵University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, ⁶Professor, Larissa, Greece
Background/Purpose: Anti-Ro52 antibodies are commonly detected in idiopathic inflammatory myopathies (IIMs), yet their clinical significance remains incompletely defined. There is evidence that it coexists with…
Abstract Number: 1198 • ACR Convergence 2025
Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab
Christina Duesing¹, Ayla Nadja Stuetz², Andrea-Hermina Györfi³, Laura-Marie Lahu⁴, Franca Sophie Deicher⁵, Gamal Chehab⁶, Jutta Richter⁷, Marie Celine van Saan⁸, Bilgesu Safak Tümerdem², Alexandru-Emil Matei⁹, Bjoern Buehring¹⁰, Ricardo Grieshaber-Bouyer¹¹, Melanie Hagen¹², Georg Schett¹³, Wolfgang Merkt¹⁴ and Jörg Distler¹⁵, ¹Klinik für Rheumatologie, Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ⁵Uniklinik Düsseldorf, Düsseldorf, Germany, ⁶Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ⁷Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Düsseldorf, Germany, ⁸Department of Rheumatology, University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University, Duesseldorf, ⁹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ¹⁰Bergisches Rheuma-Zentrum, Wuppertal, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹⁴University Hospital Düsseldorf, Düsseldorf, Germany, ¹⁵University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Treatment of anti-synthetase syndrome (ASyS) presents clinical challenges: myositis can lead to permanent disability and severe organ involvement is life-threatening.Methods: We treated three patients…
Abstract Number: 0357 • ACR Convergence 2025
Content validation of patient-reported outcome (PRO) measures for fatigue, physical function and disease activity in Polymyositis (PM)
Jason Xenakis¹, Esther Yi¹, Iyar Mazar², Sarah Knight³, Harriet Makin³, Samantha Wratten³, Rohit Aggarwal⁴ and Stephanie McKee³, ¹Pfizer Inc., New York, United States of America, New York, ²Pfizer, US, New York, ³Clarivate, London, United Kingdom, ⁴University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Polymyositis (PM) is a subtype of idiopathic inflammatory myopathy (IIM) characterized by muscle inflammation and muscle weakness. Extra muscular manifestations like interstitial lung disease…
Abstract Number: 0288 • ACR Convergence 2025
Predictors and Characteristics of Objective Flares in Adult Dermatomyositis
Didem Saygin¹, York Wang², Kathryn C. Fitzgerald³, Jemima Albayda⁴, Julie Paik⁵, Eleni Tiniakou⁶, Brittany L Adler², Andrew Mammen⁷, Lisa Christopher-Stine⁴ and Chris Mecoli², ¹Rush University Medical Center, Chicago, IL, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD, ⁶UT Health Science Houston, Houston, TX, ⁷NIH, Bethesda, MD
Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with a heterogenous clinical course. Flares often lead to increased morbidity, health care utilization, and reduced…
Abstract Number: PP05 • ACR Convergence 2025
Mastering a Rare, Autoimmune Disease: My Journey Regaining Agency Through Education, Collaboration, and Community
Mustafa Shameem

Background/Purpose: After a complex diagnostic journey, my PCP working on a rheumatological theory ordered a myositis-specific autoantibody (MSA) panel. It revealed the presence of an…
Abstract Number: 2065 • ACR Convergence 2025
Pain in Idiopathic Inflammatory Myopathies: A Global Study of Patient Experience
Lekshmi Minikumari Rahulan¹, Shounak Ghosh², Manali Sarkar³, Didem Saygin⁴, Karin Lodin⁵, Rima Shrestha⁶, Tulika Chatterjee⁷, Jessica Day⁸, Samuel Shinjo⁹, Sreoshy Saha¹⁰, Lorenzo Cavagna¹¹, Masataka Kuwana¹², Vikas Agarwal¹³ and Latika Gupta¹⁴, ¹Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, ²Department of Rheumatology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK, Wolverhampton, United Kingdom, ³Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁴Rush University Medical Center, Chicago, IL, ⁵Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Internal Medicine, University of Illinois College of Medicine Peoria, Illinois, United States, Department of Research Services, University of Illinois College of Medicine Peoria, Illinois, United States, Illinois, ⁷Department of Internal Medicine, University of Illinois College of Medicine Peoria, Illinois, United States, Illinois, ⁸Walter and Eliza Hall Institute, Melbourne, Victoria, Australia, ⁹Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ¹⁰Mymensingh Medical College, Mymensingh, Bangladesh, Mymensingh, Bangladesh, ¹¹Associate Professor in Rheumatology (Internal Medicine and Thepaeutics),University of Pavia, Pavia, Lombardy, Italy, Physician in Chief of Myositis Outpatients Clinic,Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia,Italy, Lombardia, Italy, ¹²Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁴School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Pain remains a significant yet understudied aspect of idiopathic inflammatory myopathies (IIMs), considerably reducing quality of life despite advancements in immunomodulatory therapies. Information obtained…
Abstract Number: 1218 • ACR Convergence 2025
Social Determinants Shape Health Outcomes in Idiopathic Inflammatory Myopathies: Insights from Lived Experience of 1,252 Patients
Tsvetelina Velikova¹, Kostadin Kostadinov², Emilia Naseva³, Tamar Rubinstein⁴, Manali Sarkar⁵, Lavanya Mangla⁶, Joanna Makowska⁷, Raphael Micheroli⁸, Leandro ferreryra⁹, Linda Kobert¹⁰, Ioannis Parodis¹¹, Elena Nikiphorou¹², Samuel Shinjo¹³, Carlo Vinicio Caballero Uribe¹⁴, Vincenzo Venerito¹⁵, Vikas Agarwal¹⁶ and Latika Gupta¹⁷, ¹Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ²Department of Social Medicine and Public Health, Faculty of Public Health, Medical University, Plovdiv; Health and Quality of Life in a Green and Sustainable Environment Research Group, Strategic Research and Innovation Program for the Development of MU- Plovdiv, Medical University of Plovdiv, Environmental Health Division, Research Institute at Medical University of Plovdiv, Medical University of Plovdiv,, Plovdiv, Bulgaria, ³Faculty of Public Health, Medical University of Sofia, ¹⁵ Acad. Ivan Evstratiev Geshov, ¹⁶⁰⁶ Sofia; Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ⁴Albert Einstein College of Medicine, White Plains, NY, ⁵Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁶Maulana Azad Medical College, ²-Bahadurshah Zafar Marg, New Delhi, New Delhi, India, ⁷Department of Rheumatology, Medical University of Lodz, Lodz, Poland, ⁸University Hospital Zurich, Zurich, Switzerland, ⁹HIBA, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ¹⁰The Myositis Association, Columbia, MD, ¹¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ¹²King's College London, London, United Kingdom, ¹³Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ¹⁴Department of Medicine, Hospital Universidad del Norte, Barranquilla, Atlantico, Colombi, Barranquilla, Colombia, ¹⁵Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁷School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: The impact of social determinants of health (SDoH)—including socioeconomic status, social support, and geographic context—on disease outcomes in idiopathic inflammatory myopathies (IIM) remains underexplored.…
Abstract Number: 1197 • ACR Convergence 2025
Genetic Profiling of Idiopathic Inflammatory Myopathies in Indian Patients Reveals Genotype-Phenotype Correlation
Bandana Jassal¹, Aishwarya Dhall¹, Mohammed Faruq², Danveer Bhadu¹, Uma Kumar¹ and Mehar Chand Sharma¹, ¹All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India, ²Institute of Genomics and Integrative Biology, New Delhi, Delhi, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune muscle disorders with complex genetic underpinnings. Most genetic studies have focused on limited populations. This study explores…
Abstract Number: 0344 • ACR Convergence 2025
Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
Gregory Challener¹, Zandra E. Walton¹, Christine M. Parsons¹, Aakash V. Patel², Alex Tinianow³, Molly E. Griffin¹, Raisa Lomanto Silva³, Avira Som¹, Laura J. Yockey⁴, WuQiang Fan⁵, Sheila L. Arvikar¹ and Marcy Bolster⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴MGH, Charlestown, MA, ⁵Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston, ⁶Massachusetts General Hospital, Concord, MA
Background/Purpose: Glucocorticoids are widely used in rheumatology and are associated with increased fracture risk. The 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-induced…
Abstract Number: 0284 • ACR Convergence 2025
Glucocorticoid Tapering and Relapse Risk in Anti-ARS Antibody-Positive Myositis: A Retrospective Study in a Single-Center Cohort Treated with Immunosuppressants
Ayaka Inoue¹, Takashi Yamane², Noriaki Yasuda³ and Takahisa Ohnishi¹, ¹Kakogawa Central City Hospital, Kakogawa, Japan., kakogawa-cho, kakogawa city, Hyogo, Japan, ²Kakogawa Central City Hospital, Kobe, Hyogo, Japan, ³Kakogawa Central City Hospital, Kakogawa, Japan
Background/Purpose: Anti–synthetase syndrome is generally responsive to glucocorticoid (GC) therapy, though relapse frequently complicates tapering. Prolonged GC use is associated with adverse events and decreased…
Abstract Number: PP01 • ACR Convergence 2025
When You Become the Story: A Journalist’s Approach to Managing Complex Care
Lindsay Guentzel
Background/Purpose: As a journalist, I’ve spent my career digging for answers. But when I became the story, I had to learn how to ask the…
Abstract Number: 2064 • ACR Convergence 2025
Kinematics Underlying IBM-induced Dysphagia
Kevin Renz Ambrocio¹, Vaidehi Kothari¹, Rohit Aggarwal², Anna Miles³, James L. Coyle¹, Eaman Alhassan⁴, Sandra Stinnett¹, David Lacomis¹, Lea Sayce¹ and Kendrea (Focht) Garand¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ³The University of Auckland, Auckland, New Zealand, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Dysphagia remains a key contributor to mortality in IBM due to its connection with aspiration pneumonia and malnutrition (Shelly et al., 2021). Compared to…
Abstract Number: 1217 • ACR Convergence 2025
Validation and clincial use of anti-MDA5 test – LIA versus ELISA
TING-YUAN LAN¹, pei-Hsinq lai², Tai-Ju Lee³, Ting-Wei Chang⁴, Kuan-Yen Lin⁵, Shao-Yu Pai⁶ and Ko-Jen Li⁷, ¹National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ²Taipei City Hospital, Taichung, Taiwan, ³National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, ⁵National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu City, Taiwan (Republic of China), ⁶National Taiwan University Hospital, Taichung City, Taiwan (Republic of China), ⁷National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Although immunoprecipitation (IP) remains the gold standard for detecting myositis autoantibodies, it is technically demanding and not widely available. Line immunoassay (LIA) has become…
Abstract Number: 1196 • ACR Convergence 2025
Prevalence of and Factors Associated with Chronic Opioid Use among Individuals with Inflammatory Myopathies
Anuya Natu¹, Haley Zimmerman², Kristin Wipfler³, Kaleb Michaud⁴, Yvonne Lee⁵ and Didem Saygin², ¹John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Northwestern University, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIM) can be associated with significant pain and functional impairment. While the use of opioids has been documented in other inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].